Rush, Eric http://orcid.org/0000-0002-8147-7315
Brandi, Maria Luisa http://orcid.org/0000-0002-8741-0592
Khan, Aliya http://orcid.org/0000-0003-3733-8956
Ali, Dalal S. http://orcid.org/0000-0002-5378-5548
Al-Alwani, Hatim http://orcid.org/0000-0001-9036-7903
Almonaei, Khulod http://orcid.org/0000-0002-7293-2654
Alsarraf, Farah http://orcid.org/0000-0001-9426-9702
Bacrot, Severine http://orcid.org/0000-0001-9311-5664
Dahir, Kathryn M. http://orcid.org/0000-0002-9980-9138
Dandurand, Karel http://orcid.org/0000-0003-1759-8419
Deal, Chad http://orcid.org/0000-0002-7591-4718
Ferrari, Serge Livio http://orcid.org/0000-0002-1372-4417
Giusti, Francesca http://orcid.org/0000-0002-8576-9606
Guyatt, Gordon http://orcid.org/0000-0003-2352-5718
Hatcher, Erin http://orcid.org/0000-0002-3638-4742
Ing, Steven W. http://orcid.org/0000-0002-4343-6723
Javaid, Muhammad Kassim http://orcid.org/0000-0001-7985-0048
Khan, Sarah http://orcid.org/0000-0003-3604-303X
Kocijan, Roland http://orcid.org/0000-0002-2618-1546
Lewiecki, E. Michael http://orcid.org/0000-0003-2026-9587
Linglart, Agnes http://orcid.org/0000-0003-3455-002X
M’Hiri, Iman http://orcid.org/0000-0002-6151-3366
Marini, Francesca http://orcid.org/0000-0002-3678-4922
Nunes, Mark E. http://orcid.org/0000-0001-6338-1726
Rockman-Greenberg, Cheryl http://orcid.org/0000-0002-4741-8442
Roux, Christian http://orcid.org/0000-0002-9598-9346
Seefried, Lothar http://orcid.org/0000-0003-1154-3388
Starling, Susan R. http://orcid.org/0000-0003-1813-5600
Ward, Leanne http://orcid.org/0000-0003-1557-9185
Yao, Liang http://orcid.org/0000-0003-4068-3136
Brignardello-Petersen, Romina http://orcid.org/0000-0002-6010-9900
Simmons, Jill H. http://orcid.org/0000-0002-4189-6718
Article History
Received: 30 December 2022
Accepted: 23 June 2023
First Online: 20 November 2023
Declarations
:
: These papers are retrospective reviews and did not require ethics committee approval.
: ETR has consulted for, received honoraria from, and has research supported by Alexion Pharmaceuticals, AstraZeneca Rare DiseaseMLB has received honoraria from Amgen, Bruno Farmaceutici, Calcilytix, Kyowa Kirin, UCB, grants and/or speaker for Abiogen, Alexion, Amgen, Bruno Farmaceutici, Echolight, Eli Lilly, Kyowa Kirin, SPA, Theramex, UCB, Consultant for Aboca, Alexion, Amolyt, Bruno Farmaceutici, Calcilytix, Kyowa Kirin, UCBAAK has received research grants from Alexion, Amgen, Ascendis, Chugai, Radius, Takeda, Ultragenyx and is on the advisory board for Amgen, Amolyt and TakedaSB has received advisory board participation from AlexionKMD has received research grants and honoraria from AlexionCD serves as an investigator, consultant, and speaker for Amgen; investigator for Radius; speaker for AlexionSWI has received grant funding, ad hoc advisory board participation from Alexion PharmaceuticalsMKJ has received honoria and grants from UCB, Amgen, Kyowa Kirin, Sanofi, Besin Healthcare, AbbvieRK is a speaker and has received research funding from Alexion, AstraZeneca Rare DiseaseAL is a consultant for and has received research funding and honoraria from AlexionMEN serves as a non-paid consultant (fee equivalent donated to 501(c)3 patient advocacy groups) for AlexionCR has received research grants and honoraria from Alexion, Kyowa Kirin, and RegeneronCRG is a member of the Scientific Advisory Board of the HPP Global Patient Registry sponsored by Alexion Astra-Zeneca Rare Disease. She has had received honoraria for participation on this Board and has also received honoraria for select Alexion-sponsored presentations.LS has received honoraria and grants from Alexion, Amgen, Chiesi, KyowaKirin, Novartis, Theramex, UCBJHS serves as an Investigator and consultant for AlexionSRS has received honoraria from, and has research supported by Alexion Pharmaceuticals, AstraZeneca Rare DiseaseLMW serves as a consultant to AlexionEML serves as an investigator, consultant, and speaker for Amgen; investigator for Radius; speaker for AlexionDSA, HA, KA, FA, KD, SLF, FG, GG, EH, SK, IM, FM, LY, RBP declare no conflict of interest.